How supply security and resilience are redefining partner selection

Policy momentum is reshaping how life sciences teams evaluate risk and resilience evidence, beyond price.

Across life sciences procurement cycles, resilience has shifted from an aspiration to a commercial differentiator and regulatory necessity. With policymakers now writing resilience principles into law, supply security is increasingly a hard metric, no longer relegated to just a useful element in supplier pitch decks. For procurement, regulatory and quality leaders, this is a huge change. The evidence of resilience (how it’s defined, measured, audited and contracted) is rapidly taking shape, and early movers will outpace others in both compliance and competitive positioning.

Introducing February’s sector expert

Ola Jones, Scientific Content Writer

Ola develops strategic, science-led content for clients across the pharmaceutical and life sciences industries. She brings nearly two decades of editorial and content experience, including roles with leading industry publishers and agencies. Her background spans technical writing, marketing communications and content strategy, with particular expertise in drug development, clinical research, CDMOs and high-impact therapeutic areas such as cell and gene therapy and ophthalmology.

The Critical Medicines Act 

At the center of this shift is the European Union’s (EU’s) Critical Medicines Act (CMA), adopted on January 20, 2026. Within it, the Council of the European Union agreed on a negotiating position to strengthen supply chain resilience for critical medicines across the member states [1]. The CMA is designed explicitly to reduce persistent shortages of essential medicines such as antibiotics, insulin and painkillers. It achieves this by enhancing security of supply and availability through coordinated procurement, stock-sharing mechanisms and clearer resilience criteria embedded into public procurement processes. Key elements of the CMA position include:

• Guidance on critical classification: Member states will work with the European Commission to determine whether a medicine (or its active ingredient) is produced within the EU, informing risk assessments and supply strategies.
• Contingency stock visibility: Mandatory information exchange on emergency stock levels will improve readiness and forecasting.
• Collaborative procurement incentives: Simplified requirements for joint procurement requests will lower barriers for coordinated action.
• Resilience as a procurement criterion: Public tenders for critical medicines will be required to incorporate resilience factors into evaluation matrices [1].

Alongside the CMA, broader EU efforts to prioritize supply chain resilience (from the European Medicines Agency’s (EMA’s) Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) recommendations to ancillary health system strategies) signal that supply security will be an enduring focus of European pharmaceutical policy [2].

Industry reaction: Consensus and tension

Industry responses to these proposals reflect both support for the intent and caution about execution. In coverage of the original CMA proposal, market actors such as the European Federation of Pharmaceutical Industries and Associations (EFPIA) welcomed the principle of incorporating resilience into procurement and bolstering manufacturing capacity. However, it raised concerns that overly broad application (especially without comprehensive impact assessments) could disrupt pricing regimes and create unintended barriers to market access [3].

Patient organizations, meanwhile, underscore gaps in structured cooperation and sustained financing mechanisms to underwrite long-term resilience, rather than short-term stopgaps [3].

This tension, recognizing resilience as essential while cautioning against blunt or unfunded mandates, is precisely the environment that corporate life sciences teams must navigate as they build and defend resilience evidence in supply contracts and audits.

Evidence of resilience

For pharma and medtech organizations bidding on supply contracts, whether public or private, resilience can no longer be assumed or vaguely referenced. Instead, proof of resilience must be structured, auditable and aligned with regulator expectations. Core categories of evidence that are emerging as best practice include:

• Diversification and risk mapping

Resilience begins with the breadth of supply options: multiple geographically and operationally diversified sites for active pharmaceutical ingredients (APIs) and finished products, secondary sources for critical components and transparent risk registers that identify single points of failure.

In audits, this translates into documented risk assessments that cross-reference concentration risks with mitigation plans, including alternative qualified suppliers and contingency manufacturing strategies.

• Stock and capacity verification

Regulatory guidance emphasizes visibility of contingency stocks and production capacity. Key evidence includes policy-aligned clarity on where stock is held, rotation practices to avoid expiry and governance of replenishment triggers tied to real-world demand.

• Resilience metrics in the total cost of ownership

Traditionally, price has dominated supplier evaluation. The CMA’s explicit push to leverage resilience criteria in procurement means that total cost models increasingly incorporate resilience premiums, quantifying the value of supply security, back-up capacity and rapid reallocation mechanisms.

Leading request for proposal (RFP) templates now weight resilience factors (such as multi-source coverage, contingency stock adequacy, geographic dispersion) as scored criteria alongside quality and price.

• Regulatory alignment documentation

As the CMA and similar laws are implemented, suppliers should expect auditors to request traceable alignment to regulatory frameworks: mapping production footprints against critical medicine designations, evidence of collaborative procurement readiness and documented processes for participating in stock-sharing or emergency activation mechanisms.

Embedding resilience pre-audit

Suppliers that proactively demonstrate resilience, rather than retrofitting compliance, will secure preferred status in competitive bids and be better positioned to weather market disruptions. Procurement and quality leaders can accelerate readiness by:

☑️ Integrating resilience into supplier scorecards with explicit scoring rubrics linked to documented proof points

☑️ Building cross-functional resilience playbooks that align commercial, regulatory and operational evidence for audit trails

☑️ Simulating audit scenarios based on likely regulatory expectations (e.g., contingency stock verification, alternative supply validation)

The new currency in supplier evaluation

Supply security is now a driver of strategic differentiation underpinned by rising policy expectations. The CMA and similar initiatives globally reflect a policy change that makes resilience an explicit performance metric.

For life sciences organizations, evidence of supply resilience must be rigorous, auditable and transparent. Those who can articulate and demonstrate this within contracts and audits will comply with evolving regulations and gain a competitive edge in partner selection.

References

1. https://www.consilium.europa.eu/en/press/press-releases/2025/12/02/critical-medicines-act-council-agrees-its-position-on-new-rules-to-tackle-shortages/
2. https://www.ema.europa.eu/en/documents/other/mssg-recommendations-strengthen-supply-chains-critical-medicinal-products_en.pdf
3. https://pharmaphorum.com/news/eu-proposes-legislation-bolster-medicines-supply-chain